A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration
暂无分享,去创建一个
M. Mahajan | S. Friedman | Xintong Chen | J. Llovet | M. Colombo | R. Chung | K. Kojima | Y. Hoshida | A. Villanueva | Xiaochen Sun | M. Fiel | M. Kobayashi | H. Kumada | Lindsay Y King | V. Nair | Shun H. Yip | M. Deshmukh | Poh Seng Tan | A. Sangiovanni | M. Iavarone | A. Venkatesh | Claudia Canasto-Chibuque | Kara B. Johnson | M. Fiel
[1] M. Manns,et al. Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters , 2014, Gut.
[2] Peter J. Richardson,et al. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. , 2014, Gastroenterology.
[3] M. Sherman,et al. Burden of disease and cost of chronic hepatitis C virus infection in Canada , 2014 .
[4] Raymond T Chung,et al. Curing chronic hepatitis C--the arc of a medical triumph. , 2014, The New England journal of medicine.
[5] M. Makuuchi,et al. Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study , 2014, Journal of Gastroenterology.
[6] Anthony D. Schmitt,et al. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma , 2014, Hepatology.
[7] Jian-Bing Fan,et al. Transcriptome Profiling of Archived Sectioned Formalin-Fixed Paraffin-Embedded (AS-FFPE) Tissue for Disease Classification , 2014, PloS one.
[8] J. Marrero,et al. Machine Learning Algorithms Outperform Conventional Regression Models in Predicting Development of Hepatocellular Carcinoma , 2013, The American Journal of Gastroenterology.
[9] V. de Lédinghen,et al. Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection , 2013, Annals of Internal Medicine.
[10] S. Imbeaud,et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. , 2013, Gastroenterology.
[11] J. Luk,et al. Circulating markers for prognosis of hepatocellular carcinoma. , 2013, Expert opinion on medical diagnostics.
[12] M. Zálešák,et al. Current and Future Disease Progression of the Chronic HCV Population in the United States , 2013, PloS one.
[13] Levi A Garraway,et al. Genomics-driven oncology: framework for an emerging paradigm. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] S. Gabriel,et al. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. , 2013, Gastroenterology.
[15] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[16] M. Manns,et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. , 2012, JAMA.
[17] Bernadette A. Thomas,et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.
[18] Y. Hoshida,et al. Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. , 2012, Current cancer drug targets.
[19] R. Monina Klevens,et al. The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007 , 2012, Annals of Internal Medicine.
[20] Scott L. Pomeroy,et al. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples , 2011, Acta Neuropathologica.
[21] E. Schiff,et al. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. , 2011, Gastroenterology.
[22] L. Waldron,et al. mRNA transcript quantification in archival samples using multiplexed, color-coded probes , 2011, BMC biotechnology.
[23] Arthur Liberzon,et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. , 2011, Gastroenterology.
[24] J. Bruix,et al. Management of hepatocellular carcinoma: An update , 2011, Hepatology.
[25] William M. Lee,et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. , 2011, Gastroenterology.
[26] H. El‐Serag,et al. Utilization of Surveillance for Hepatocellular Carcinoma Among Hepatitis C Virus–Infected Veterans in the United States , 2011, Annals of Internal Medicine.
[27] Yujin Hoshida,et al. Nearest Template Prediction: A Single-Sample-Based Flexible Class Prediction with Confidence Assessment , 2010, PloS one.
[28] H. El‐Serag,et al. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[29] Scott L. Friedman,et al. Evolving challenges in hepatic fibrosis , 2010, Nature Reviews Gastroenterology &Hepatology.
[30] S. Koscielny. Why Most Gene Expression Signatures of Tumors Have Not Been Useful in the Clinic , 2010, Science Translational Medicine.
[31] R. Sterling,et al. Systematic review: non‐invasive methods of fibrosis analysis in chronic hepatitis C , 2009, Alimentary pharmacology & therapeutics.
[32] J. Crowley,et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). , 2009, JAMA.
[33] Kenji Ikeda,et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. , 2008, The New England journal of medicine.
[34] Richard Simon,et al. The Use of Genomics in Clinical Trial Design , 2008, Clinical Cancer Research.
[35] W. Kim,et al. The model for end‐stage liver disease (MELD) , 2007, Hepatology.
[36] M. Colombo,et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. , 2004, Gastroenterology.
[37] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[38] K. Ishak,et al. Histological grading and staging of chronic hepatitis. , 1995 .
[39] P. Bedossa,et al. Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients with Chronic Hepatitis C , 1994 .
[40] M. Colombo,et al. Hepatocellular carcinoma in Italian patients with cirrhosis. , 1991, The New England journal of medicine.
[41] J R Beck,et al. A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making. , 1982, The American journal of medicine.
[42] William Sanchez,et al. Chemopreventive strategies in hepatocellular carcinoma , 2014, Nature Reviews Gastroenterology &Hepatology.
[43] M. Sherman,et al. Burden of disease and cost of chronic hepatitis C infection in Canada. , 2014, Canadian journal of gastroenterology & hepatology.
[44] J. Dufour. Modern hepatomancy. , 2013, Gastroenterology.
[45] V. Mazzaferro,et al. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer , 2012 .
[46] Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. , 1994, Hepatology.
[47] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.